Ghani Global Glass 9MFY26 Profit Plunges 71% as Exports Collapse

Ghani Global Glass, a Lahore-based maker of glass tubes, vials and ampoules for the healthcare industry, reported a sharp drop in its nine-month FY26 profit. Net profit fell 71 percent to Rs70.66 million for the nine months ended 31 March 2026, from Rs243.22 million a year earlier. A collapse in exports, thinner margins and heavy finance costs all worked against the company.

What the Ghani Global Glass nine-month results showed

Ghani Global Glass saw net sales slip only 4 percent to Rs2,035.91 million, so the profit fall was not mainly about lower total revenue. The damage came elsewhere. Export sales plummeted 61 percent to Rs52.53 million from Rs134.08 million, a much higher-margin part of the mix. Gross profit fell 11 percent to Rs490.40 million, so the gross margin narrowed. Below the operating line, finance costs stayed high at Rs266.94 million, roughly flat against shrinking profit, and other income crashed 89 percent to Rs9.95 million from Rs90.68 million. Administrative expenses rose 37 percent and statutory levies jumped 145 percent. The combined effect dragged net profit down 71 percent, with EPS of Rs0.30 against Rs1.01.

Why exports and finance costs matter for a glass maker

Glass manufacturing is energy-heavy and capital-heavy, so two things shape the result: the margin on what the company sells, and the cost of the debt that funds the furnaces and plant. Exports usually carry better prices than domestic sales, so a 61 percent fall in export revenue hurts the margin even when total sales barely move. At the same time, finance costs of Rs267 million eat a fixed slice of profit regardless of how trading goes, which is painful in a weak year. The near-disappearance of other income, which had cushioned the prior year, removed a prop that had been holding the bottom line up. Higher administrative costs and a sharp rise in levies added to the squeeze.

Which stocks, and why

This is a direct, company specific result for Ghani Global Glass, and the read is negative. The 71 percent profit fall reflects a genuine deterioration: lost export business, a thinner gross margin, and a heavy debt burden that does not ease when profits shrink. It is marked at a high influence level because the decline is large and touches the core economics of the business, from exports to margins to finance costs, and the export weakness looks structural rather than a one-off blip.

What to watch

The signals to track are export sales, which need to recover to rebuild the margin, and the gross margin itself, which shows whether pricing and energy costs are stabilising. Finance costs are the other key item, so watch the policy rate and the company's debt load, since high fixed interest is amplifying the pain. Demand from the pharmaceutical sector, the main buyer of GGGL's vials and ampoules, will shape the full-year outcome.